Please wait, loading...
Lipotech was established recently in Delaware on the basis of a technology platform for development of Liposomal Oncology drugs – an ongoing heritage with through from Sequus Pharma of J&J and Regulon Inc from Silicon Valley
Liposomal Technology Platform of Lipotech starts with Liposomal Cisplatin with Orphan Drug Designation for Pancreatic Cancer from European Medicines Agency and combines it with the patented use of Inhalation Therapy of Rutgers University in New Jersey.
The advantage of Liposomal Oncology technology platform gives Lipotech the opportunity to apply it in i.v. form as well as inhalation chemotherapies through a nebulizer – mask combination Medical Device the patent of which will be taken soon.
Lipotech has made strategic collaborations with ForDoz Pharma from New Jersey for pilot manufacturing of Liposomal Cisplatin for having the vials to be used for new clinical trials that will be done in SCLC (Small Cell Lung Cancer) and Pediatric Lung Cancer to be held in multicenter studies in Greece, Turkey, Georgia and in USA.
Recently there has been strong interest from different oncology companies for co-development and manufacturing of new oncology agents like Onko Kocsel AS from Turkey with a large generic oncology portfolio manufactured in GMP audited facilities located in Istanbul, Turkey